Skip to content

Opko Health OPK Investment Proceeds

Investment Proceeds at other companies

Precigen logo
PrecigenPGEN
$55.1M+1,105%
Immunome logo
ImmunomeIMNM
$0-100%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$88M-35.8%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$1.3M-96.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$752.82M+52.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
$24.1M-45.5%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B-22.4%
P/S1.9×-0.2×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's investment proceeds?
Opko Health (OPK) reported investment proceeds of $0 in Q1 2026.
How has Opko Health's investment proceeds changed year-over-year?
Opko Health's investment proceeds decreased by 100.0% year-over-year, from $51.66M to $0.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.